Drug Interactions between AccessPak for HIV PEP Expanded with Viracept and Recombivax HB Dialysis Formulation
This report displays the potential drug interactions for the following 2 drugs:
- AccessPak for HIV PEP Expanded with Viracept (emtricitabine/nelfinavir/tenofovir disoproxil)
- Recombivax HB Dialysis Formulation (hepatitis b adult vaccine)
Interactions between your drugs
No interactions were found between AccessPak for HIV PEP Expanded with Viracept and Recombivax HB Dialysis Formulation. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
AccessPak for HIV PEP Expanded with Viracept
A total of 699 drugs are known to interact with AccessPak for HIV PEP Expanded with Viracept.
- Accesspak for hiv pep expanded with viracept is in the drug class antiviral combinations.
- Accesspak for hiv pep expanded with viracept is used to treat HIV Infection.
Recombivax HB Dialysis Formulation
A total of 298 drugs are known to interact with Recombivax HB Dialysis Formulation.
- Recombivax hb dialysis formulation is in the drug class viral vaccines.
- Recombivax hb dialysis formulation is used to treat Hepatitis B Prevention.
Drug and food interactions
tenofovir food
Applies to: AccessPak for HIV PEP Expanded with Viracept (emtricitabine / nelfinavir / tenofovir disoproxil)
Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.
References (1)
- (2001) "Product Information. Viread (tenofovir)." Gilead Sciences
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.